12:00 AM
 | 
Nov 14, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/11 cls
Inhibitex Inc. (NASDAQ:INHX) Deutsche Bank Robyn Karnauskas Price target Buy 9% $9.29
Karnauskas raised her target to $15 from $9 after Inhibitex reported topline data showing that once-daily 200 mg INX-189 as monotherapy reduced median HCV RNA from baseline to day seven by 4.25 log10 IU/mL in the first cohort of a Phase Ib trial in treatment-naive patients with chronic HCV genotype 1 infection (see BioCentury, Nov. 7). She anticipates a 2017 launch of the phosphoramidate nucleoside analog NS5B polymerase inhibitor, with peak annual worldwide sales of $5B.
pSivida Corp. (NASDAQ:PSDV; ASX:PVA) Ladenburg Thalmann Juan Sanchez Downgrade...

Read the full 726 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >